311 related articles for article (PubMed ID: 30352843)
1. Heated tobacco products likely appeal to adolescents and young adults.
McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
[TBL] [Abstract][Full Text] [Related]
2. IQOS: examination of Philip Morris International's claim of reduced exposure.
St Helen G; Jacob Iii P; Nardone N; Benowitz NL
Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
[TBL] [Abstract][Full Text] [Related]
3. IQOS labelling will mislead consumers.
McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
[TBL] [Abstract][Full Text] [Related]
4. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
McKelvey K; Baiocchi M; Halpern-Felsher B
Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
[TBL] [Abstract][Full Text] [Related]
5. Revolution or redux? Assessing IQOS through a precursor product.
Elias J; Dutra LM; St Helen G; Ling PM
Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
[TBL] [Abstract][Full Text] [Related]
6. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims.
Popova L; Lempert LK; Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208
[TBL] [Abstract][Full Text] [Related]
7. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
[TBL] [Abstract][Full Text] [Related]
8. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.
Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y
Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166
[TBL] [Abstract][Full Text] [Related]
9. Heated tobacco product regulation under US law and the FCTC.
Lempert LK; Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
[TBL] [Abstract][Full Text] [Related]
10. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
Lempert LK; Bialous S; Glantz S
Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
[TBL] [Abstract][Full Text] [Related]
11. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
Tob Control; 2023 Mar; ():. PubMed ID: 36958825
[TBL] [Abstract][Full Text] [Related]
12. Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland.
Hair EC; Bennett M; Sheen E; Cantrell J; Briggs J; Fenn Z; Willett JG; Vallone D
Tob Control; 2018 Nov; 27(Suppl 1):s70-s73. PubMed ID: 29764957
[TBL] [Abstract][Full Text] [Related]
13. Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product.
Salman R; Talih S; El-Hage R; Haddad C; Karaoghlanian N; El-Hellani A; Saliba NA; Shihadeh A
Nicotine Tob Res; 2019 Aug; 21(9):1285-1288. PubMed ID: 30476301
[TBL] [Abstract][Full Text] [Related]
14. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
Kim J; Yu H; Lee S; Paek YJ
Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
[TBL] [Abstract][Full Text] [Related]
15. Analysis of FDA's IQOS marketing authorisation and its policy impacts.
Lempert LK; Glantz S
Tob Control; 2020 Jun; ():. PubMed ID: 32601147
[TBL] [Abstract][Full Text] [Related]
16. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
[TBL] [Abstract][Full Text] [Related]
17. Correlates of Perceptions, Use, and Intention to Use Heated Tobacco Products Among US Young Adults in 2020.
Duan Z; Wysota CN; Romm KF; Levine H; Bar-Zeev Y; Choi K; Berg CJ
Nicotine Tob Res; 2022 Nov; 24(12):1968-1977. PubMed ID: 35901840
[TBL] [Abstract][Full Text] [Related]
18. Point-of-sale marketing of heated tobacco products in Israel: cause for concern.
Halpern-Felsher B
Isr J Health Policy Res; 2019 May; 8(1):47. PubMed ID: 31133053
[TBL] [Abstract][Full Text] [Related]
19. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
Berg CJ; Bar-Zeev Y; Levine H
Sage Open; 2020; 10(1):. PubMed ID: 32719733
[TBL] [Abstract][Full Text] [Related]
20. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product.
Max WB; Sung HY; Lightwood J; Wang Y; Yao T
Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
